Literature DB >> 4588620

Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice.

O Stutman.   

Abstract

Athymic-nude (nu/nu) mice and normal (nu/+) mice showed no differences in either latent period or incidence of local sarcomas or lung adenomas within 120 days after administration of 3-methylcholanthrene at birth. However, nu/nu mice were incapable of rejecting allogeneic skin grafts for the duration of the experiment. These results argue against an active role of thymus-dependent immunity as a surveillance mechanism preventing tumor development.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4588620     DOI: 10.1126/science.183.4124.534

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  62 in total

1.  The role of the immune response in oncogenesis.

Authors:  H F Jeejeebhoy
Journal:  In Vitro       Date:  1975 May-Jun

2.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

3.  Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis.

Authors:  Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

Review 4.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 5.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 6.  Tumor cells do not arise frequently.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 7.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Natural killing activity is associated with progression of gastric cancer.

Authors:  K Ono; Y Imazono; T Misawa; J Nishimura; H Nawata
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

9.  Antiinflammatory reaction associated with murine L1210 leukemia.

Authors:  B H Lau; T D Masek; W T Chu; J M Slater
Journal:  Experientia       Date:  1976-12-15

Review 10.  A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas.

Authors:  T H Schreiber; E R Podack
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.